GHK-Cu: 50 Years of Research, None on Injection

NPR published a report by Will Stone on 7 September 2026 about copper peptides, and the thing that has changed is not the molecule. It is the route.

The compound is GHK-Cu, a tripeptide with a copper ion, and NPR describes topical serums and creams that have been on the market for decades and studied in human trials. What is new, the report says, is that many people are now taking it as a subcutaneous injection, sometimes stacked with other peptides promoted for tissue repair and anti-aging.

NPR states the position plainly: there is no data from published human studies to show this practice is safe and effective.

A framing note. Peptra Labs supplies GHK-Cu as characterised reference material to laboratories on a research use only basis. Nothing below is guidance about human use, and the practice the report describes sits outside anything we supply material for.

The evidence GHK-Cu actually has

The history in the piece is longer than the trend suggests.

NPR traces the compound to the early 1970s, when a chemist named Loren Pickart isolated GHK, a string of three amino acids, after noticing that bathing liver cells in the laboratory with plasma from younger adults helped revive them. By collecting blood from medical students and comparing it with their older professors, he established that levels decline with age.

Since then, the report says, studies have found that the copper complex stimulates collagen production and other compounds involved in skin remodelling, triggers the growth of new blood vessels, and has anti-inflammatory effects.

The qualifier NPR attaches to that record is the part worth carrying. The controlled studies in humans have focused almost exclusively on skin health and aesthetics, and to a lesser extent on wound healing and hair growth. They are described as generally small trials funded by the cosmetic industry, showing that a serum or cream improves skin thickness and elasticity, decreases wrinkles and promotes hair growth.

David Goldberg, director of cosmetic dermatology for the Schweiger Dermatology Group and a clinical professor at the Icahn School of Medicine at Mount Sinai, is quoted saying the science behind this is very solid, describing the peptide as bolstering collagen, part of what he calls the scaffolding of the skin, and putting it on par with topicals containing vitamin C and antioxidants.

Small, industry-funded and topical is a real evidence base. It is also a specific one, and it does not transfer to a different route of administration.

Why the GHK-Cu record stops where it does

Beyond skin, the report describes preclinical work only.

In animal studies, NPR says, GHK-Cu sped up wound healing and helped repair organs, including fibrosis in the lungs. Warren Ladiges, a professor at the University of Washington School of Medicine who has studied the peptide for many years, is quoted saying his experiments show it stimulates a number of pathways associated with ageing, and that it alleviated some symptoms of Alzheimer’s in mouse models.

Efforts to move that work into human trials have been fruitless, and the reason NPR gives is structural rather than scientific.

GHK-Cu is a naturally occurring molecule. That makes it difficult for a drug company to patent without creating a unique version and then paying for human trials. Ladiges is quoted saying it would require huge investment, and that it is probably never going to get FDA approval.

That paragraph explains the whole situation better than any argument about efficacy. The gap in the human record is not evidence that the molecule fails. It is evidence that nobody has an economic reason to run the trial, which is a different fact with different consequences.

The route is what changed about GHK-Cu, not the compound

Goldberg tells NPR it is possible there are added benefits to injecting, in part because the molecule does not easily penetrate deeper into the skin when applied topically. That is a plausible pharmacokinetic argument and the report treats it as one.

He and other dermatologists are nonetheless advising patients to hold off from injecting anything, and he is quoted saying he is not going to sleep well at night until the human studies are actually done.

Ladiges says GHK-Cu is generally quite safe based on animal studies, and names two specific risks of injection: overloading the system with too much copper, and triggering a dangerous immune reaction. His own line about the practice is the sharpest in the piece, that he would not do it to himself.

The researcher who thinks the compound could matter for longevity and the dermatologist who calls the topical science solid land in the same place on the injectable question, which is worth noticing.

The identity problem underneath the GHK-Cu question

Marisa Garshick, at MDCS Dermatology, raises the concern that is not about biology at all.

She tells NPR that much of the worry centres on consumers sourcing injectable formulations from unregulated suppliers, with no assurance about the quality or the amount in the vial, and that whether or not it is even a copper peptide is always a concern. The stakes, she says, are much higher when you are injecting something.

That is an identity and characterisation problem rather than a pharmacology one, and it is measurable. A batch either has a certificate of analysis, an identity confirmation and traceable handling, or it does not. We have written about the risk profile of research peptides and covered a case report of a product bought online where the same ambiguity made the clinical picture impossible to resolve.

What one clinic sees with GHK-Cu

The most concrete section of the report comes from Erik Marks, a doctor of nursing practice who runs a wellness and longevity clinic near Seattle.

He tells NPR that most of his consultations about the compound are with people who already bought it from an online seller and injected it themselves, and then became worried about safety. The problems he describes range from injection site irritation and infections to more serious issues affecting the liver. He is quoted describing patients whose liver enzymes were elevated and whose copper was elevated, who had been injecting far too much and had not been checking laboratory work at all.

NPR adds the caveat that matters: in those circumstances it is unclear whether the copper peptide, or some other undisclosed substance or impurity, is responsible.

Marks offers the compound himself as a serum and a cream, and occasionally as an injection, sourced from a licensed compounding pharmacy. His clinical impression is still that the topicals work much better for skin and hair, and that injecting tends to have minimal impact. The jury, he says, is still out.

Where the regulation stands

Compounding pharmacies in the United States are not technically allowed to offer the peptide for injection in humans, though NPR reports the administration has signalled that could change.

An FDA advisory panel recommended earlier this summer that the government reclassify half a dozen of these compounds. The report says the group will meet again in February to review the evidence for GHK-Cu as an injectable, among others.

We covered the 503A bulks list vote when that committee met and made the point that applies again here. An advisory recommendation is not an approval, and a decision that a compounding pharmacy may prepare something is not a finding that it works.

What it means for the catalogue

Our position on GHK-Cu is narrow and the distinction only holds if we keep stating it.

The literature we cite for this compound is the topical human work and the preclinical animal work, which is what what GHK-Cu does to gene expression covers, alongside a review of its use in aesthetic medicine and the 2026 skin studies. None of that is a human injectable literature, because one does not exist, and we are not going to write as though it does.

What characterisation answers is Garshick’s question rather than Ladiges’ question. Documentation establishes what is in a vial. It says nothing about what happens when a compound is given by a route nobody has studied, and February will not change that either.

References

• Stone W. The copper peptide trend has gone from creams to injections, ahead of the science. NPR, Morning Edition, 7 September 2026

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.